Ensign Group (ENSG) has just made two governance and financing moves that matter for shareholders. Freshly amended bylaws and an expanded revolving credit facility now frame how the company runs meetings and funds future capital needs.
At a share price of $173.20, Ensign Group has seen recent momentum cool slightly, with the 7 day share price return down 3.25% and the 30 day share price return down 2.78%. However, the 3 year total shareholder return of 82.21% and 5 year total shareholder return of 115.23% point to a much stronger longer term record.
Compare Ensign Group's governance and balance sheet moves with other healthcare operators by scanning a curated set of list of solid balance sheet and fundamentals (53 results) .
The bylaw refresh and larger credit line could signal confidence in Ensign Group's operating model or simply reflect investors reassessing shorter term risks. Which story do the current valuation markers really point to next?
Price-to-Earnings of 26.4x: Is it justified?
On simple valuation markers, Ensign Group does not screen as cheap. The stock trades on a P/E of 26.4x, which places a premium on its $173.20 share price compared with several reference points.
The P/E ratio compares what investors are paying today for each dollar of Ensign Group's earnings. It can reflect how the market weighs the company's earnings record, forecasts and perceived quality of profits. With Ensign Group reporting 14.2% annual earnings growth over the past 5 years and earnings growth of 17.3% over the past year, that premium multiple is being applied to a business with an established profit track record, rather than one that is still loss making.
However, the current 26.4x P/E is higher than both the US Healthcare industry average of 24.8x and the peer average of 15.2x. It is also slightly above the estimated fair P/E of 26.3x that the fair ratio model suggests the market could align with over time, which indicates only a very small gap between price and that reference level.
To see how that fair ratio benchmark is calculated and how Ensign Group compares to peers on this metric, review the Explore the SWS fair ratio for Ensign Group .
Result: Price-to-Earnings of 26.4x (OVERVALUED)
However, Ensign Group's higher P/E and reliance on US healthcare reimbursement and regulation still leave room for sentiment to turn quickly if those supports weaken.
Find out about the key risks to this Ensign Group narrative.
Another view using the SWS DCF model
The earlier P/E workup paints Ensign Group as expensive, yet the SWS DCF model points the other way. With a fair value estimate of $198.98 versus the current $173.20 share price, the stock screens about 13% below that reference level and screens as undervalued.
For investors, that split picture raises a practical question. Should more weight sit with the simple earnings multiple that looks full, or with a cash flow model that suggests some upside is still on the table, especially if assumptions or sentiment shift again?
To understand how this cash flow view is built and what assumptions sit behind it, take a closer look at the Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Ensign Group for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 50 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this mix of signals on Ensign Group feels finely balanced, consider acting while the data is fresh and pressure test the optimism for yourself using the 4 key rewards .
Looking for more Ensign Group style investment ideas?
Do not stop with Ensign Group. Use the Simply Wall Street Screener today to quickly surface fresh stock ideas that fit the way you like to invest.
-
Target companies that combine quality and attractive pricing by reviewing our curated set of 50 high quality undervalued stocks .
-
Prioritise resilience and capital protection by focusing on a 74 resilient stocks with low risk scores that highlights stocks with stronger risk profiles.
-
Hunt for lesser known opportunities with solid fundamentals using a hand picked shortlist of 19 high quality undiscovered gems .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENSG .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
